Treatment of hepatocellular carcinoma
- PMID: 20130431
- DOI: 10.1159/000258495
Treatment of hepatocellular carcinoma
Abstract
As a result of progresses in surveillance programs and improvements in diagnosis, an increased number of hepatocellular carcinomas are diagnosed in early stage, when effective treatment options are available. Surgical resection, liver transplantation and radiofrequency ablation are considered potentially curative treatments and may be successfully applied when the disease is limited. In intermediate and advanced stages only palliative therapies can be employed and chemoembolization and the oral dual inhibitor sorafenib are considered the treatments of choice. Future directions will explore the role of sorafenib in the adjuvant setting, the addition of sorafenib to chemoembolization procedures and the combination of sorafenib with chemotherapeutic agents or other biological drugs in advanced stages of disease.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
Chemoembolization and bland embolization: a critical appraisal.Clin Liver Dis. 2005 May;9(2):287-300, vii. doi: 10.1016/j.cld.2004.12.011. Clin Liver Dis. 2005. PMID: 15831274 Review.
-
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20. doi: 10.1002/lt.20034. Liver Transpl. 2004. PMID: 14762851 Review.
-
Nonsurgical treatment of hepatocellular carcinoma.Liver Transpl. 2000 Nov;6(6 Suppl 2):S11-5. doi: 10.1053/jlts.2000.18684. Liver Transpl. 2000. PMID: 11084079 Review.
-
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?Oncologist. 2010;15 Suppl 4:42-52. doi: 10.1634/theoncologist.2010-S4-42. Oncologist. 2010. PMID: 21115580 Review.
-
Novel advancements in the management of hepatocellular carcinoma in 2008.J Hepatol. 2008;48 Suppl 1:S20-37. doi: 10.1016/j.jhep.2008.01.022. Epub 2008 Feb 12. J Hepatol. 2008. PMID: 18304676 Review.
Cited by
-
CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.Cancer Manag Res. 2020 Sep 24;12:8951-8964. doi: 10.2147/CMAR.S252679. eCollection 2020. Cancer Manag Res. 2020. PMID: 33061591 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials